moxifloxacin has been researched along with Extensively Drug-Resistant Tuberculosis in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Drlica, K; Singh, A; Zhao, X | 1 |
| Al-Hajoj, S; Varghese, B | 1 |
| Aubry, A; Bernard, C; Chauffour, A; Chavanet, P; El Helali, N; Jarlier, V; Maitre, T; Petitjean, G; Reibel, F; Veziris, N | 1 |
| Chen, YH; Huang, CH; Kuo, CY; Lu, PL; Wang, WH | 1 |
| Dong, L; Fu, Y; Huang, H; Huo, F; Jing, W; Li, Y; Ma, Y; Pang, Y; Zhao, L; Zong, Z | 1 |
| Andres, S; Beckert, P; Heyckendorf, J; Hillemann, D; Kohl, TA; Köser, CU; Lange, C; Merker, M; Moradigaravand, D; Niemann, S; Olaru, ID; Parkhill, J; Peacock, SJ; Schleusener, V; Schön, T; Sturegård, E | 1 |
| Bethunaickan, R; Chandramohan, Y; Padmanaban, V; Ranganathan, UD; Swaminathan, S; Tripathy, S | 1 |
| Boutou, A; Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Papaioannou, M; Zarogoulidis, K | 1 |
| Lu, JM; Sha, W; Xiao, HP; Yang, H; Zhang, LL; Zhang, Q | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Blackmore, T; McNaughton, A; McNaughton, H | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Badri, M; Dheda, K; Shean, K | 1 |
| Aggarwal, D; Janmeja, AK; Mohapatra, PR | 1 |
| Agnihotri, SP; Gupta, P; Gupta, S; Jain, NK; Sharma, KK | 1 |
| Freeman, JT; Goh, TL; Jones, KL; Towns, CR; Wong, CS | 1 |
| Chung, HS; Han, SK; Kim, DK; Kim, JY; Kim, YW; Lee, CH; Lee, CT; Lee, J; Lee, JH; Lee, SM; Yang, SC; Yim, JJ; Yoo, CG; Yoon, HI | 1 |
| Abbate, E; Ambroggi, M; Cufré, M; García, A; Gonzalez Montaner, P; Natiello, M; Ritacco, V; van Soolingen, D; Vescovo, M | 1 |
2 review(s) available for moxifloxacin and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Cysteine; Disinfectants; DNA Gyrase; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; NAD; Reactive Oxygen Species; Tuberculosis, Multidrug-Resistant | 2022 |
18 other study(ies) available for moxifloxacin and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin | 2010 |
First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant
Topics: Adult; Aged; Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Genes, Bacterial; Humans; Kanamycin; Male; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Retrospective Studies; Risk Factors; Saudi Arabia; Tandem Repeat Sequences; Tuberculosis, Pulmonary | 2017 |
Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Levofloxacin; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome | 2017 |
Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
Topics: Aminosalicylic Acid; Antitubercular Agents; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Streptomycin; Taiwan | 2018 |
Topics: Antitubercular Agents; Beijing; China; Clofazimine; Diarylquinolines; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2017 |
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Bacterial Typing Techniques; Cohort Studies; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genome, Bacterial; Genotype; Humans; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Phenotype; Rifampin; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2018 |
In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis, Multidrug-Resistant; Xanthenes | 2019 |
Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study.
Topics: Adult; Aged; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Greece; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Outpatients; Rifampin; Tuberculosis, Pulmonary | 2015 |
[Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
Topics: Aminosalicylic Acids; Antibiotics, Antitubercular; Drug Synergism; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Retreatment; Rifabutin; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary | 2016 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; South Africa; Treatment Outcome | 2008 |
Treatment of extensively drug-resistant tuberculosis.
Topics: Acetamides; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Linezolid; Moxifloxacin; Oxazolidinones; Quinolines | 2009 |
Extensively drug resistance (XDR) tb is not always fatal.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Aza Compounds; Capreomycin; Clarithromycin; Clofazimine; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; India; Injections; Male; Moxifloxacin; Quinolines; Sputum; Treatment Outcome | 2009 |
Extensively drug-resistant tuberculosis: New Zealand's first case and the challenges of management in a low-prevalence country.
Topics: Acetamides; Adult; Aminosalicylic Acid; Antitubercular Agents; Aza Compounds; Cycloserine; Emigrants and Immigrants; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Imipenem; Linezolid; Lymph Nodes; Male; Moxifloxacin; Myanmar; New Zealand; Oxazolidinones; Quinolines; Radiography | 2011 |
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Odds Ratio; Ofloxacin; Quinolines; Recurrence; Remission Induction; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2011 |
Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine.
Topics: Acetamides; Adult; Antitubercular Agents; Argentina; Aza Compounds; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Linezolid; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Oxazolidinones; Quinolines; Retrospective Studies; Thioridazine; Treatment Outcome; Tuberculosis, Pulmonary | 2012 |